CHO, MI YOUNGKR,조미영,LEE, SEUNG HYUNKR,이승현,CHEONG, KWANG HOKR,정광호,KOH, YOUNG JUNKR,고영준,LEE, JUNG WOOKKR,이정욱,LINPOWEITW,린포웨이,HWANG, JAE WOONGKR,황재웅
申请号：
KR1020130089280
公开号：
KR1020150014551A
申请日:
2013.07.29
申请国别(地区):
KR
年份:
2015
代理人:
摘要：
Provided in an embodiment is polypeptide. Provided in another embodiment are one or more kind of a heavy chain complementarity determining region selected among a group consisting of CDR-H1,CDR-H2, and CDR-H3, one or more kind of a low chain complementarity determining region or an anti-EGFR including the combination of the same or an antibody combined fragment of the same. Provided in an embodiment is polypeptide having a new sequence. The polypeptide can have a function of an anti-EGFR antibody as CDR.COPYRIGHT KIPO 2015항 EGFR scFv 단편, 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체, 및 이를 포함하는 암의 예방 및/또는 치료용 약학적 조성물이 제공된다.
